Clinical Trial Update: FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

View source ↗

Summary

A Mayo Clinic-sponsored trial is evaluating FDG-PET imaging to diagnose and risk stratify subclinical immune checkpoint inhibitor-induced myocarditis in cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Checkpoint Inhibitor-induced Myocarditis
• Myocarditis

Snippet

Sponsor: Mayo Clinic | Conditions: Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis, Myocarditis | Status: RECRUITING